1658 University Avenue
7 articles with BioAge Labs
BioAge Signs Exclusive Agreement With Amgen To Develop and Commercialize Amgen’s Phase 1 APJ Agonist To Treat Diseases of Aging
BioAge Labs, Inc. a biotechnology company developing medications that target the molecular causes of aging to extend healthy human life, announced that it has entered into an exclusive worldwide license agreement with Amgen, Inc.
BioAge Initiates Phase 2 Trial of BGE-175 to Treat COVID-19 by Reversing Immune Aging, a Key Cause of Morbidity and Mortality in Older Patients
BGE-175 prevents lethality in murine models of SARS-CoV-2 viral challenge Multi-center, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of daily oral BGE-175 for up to 14 days
BioAge Labs, Inc., is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference (JPM) on Tuesday, January 12, 2021 at 2:00pm ET. The BioAge leadership team also will be available for one-on-one meetings via BIO Partnering @ JPM from January 11-15, 2021. Kristen Fortney, BioAge’s chief executive officer, will provide an overview of BioAge’s systems biology and data-driven platform to map the
Check out some news happening today around the biopharma industry.
BioAge Labs, Inc., a biotechnology company developing medicines to treat aging and aging-related diseases, today announced that it has raised $90 million in an oversubscribed Series C financing
BioAge Discovers Key Pathway and Identifies Promising Phase 2 Ready Drug to Treat and Reverse Immune Aging, a Root Cause of COVID-19 Morbidity and Mortality in Older Patients
BioAge Plans Phase 2 Clinical trial in Hospitalized COVID-19 Patients Clinical development plan supported by potent inhibition of PGD2 DP1 Receptor by BGE-175 , activating immune-modulating mechanisms that result in 100% survival in aged preclinical models of coronavirus BioAge’s proprietary human aging data links activation of PGD2 DP1 signaling to increased risk of mortality and susceptibility to infections RICHMOND, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- BioAge Labs, Inc., a biot
BioAge Signs Exclusive License Agreement with Taisho to Develop and Commercialize Taisho’s Phase 1 HIF-PH Inhibitor to Treat Aging
BioAge’s proprietary platform of human aging data demonstrates that the Hypoxia-inducible factor (HIF) pathway is linked to healthspan and lifespan